Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945291 | 0.92 | EPHX2 (0.39) | GPR119EPHX2HPGDSMN1; SMN2CHRM4 | |
| SCHEMBL238436 | 0.84 | GPR119 (0.44) | GPR119ACACBHRH2HRH1 | |
| SCHEMBL946687 | 0.80 | IDH1 (0.45) | GPR119EPHX2HRH3IDH1 | |
| SCHEMBL14402686 | 0.79 | GPR119 (0.41) | GPR119ACACBHRH2HRH1 | |
| SCHEMBL3722073 | 0.77 | ITGB3 (0.40) | GPR119EPHX2DGAT1 | |
| SCHEMBL945292 | 0.77 | GPR119 (0.47) | GPR119HRH3HRH2HRH1IDH1 | |
| SCHEMBL14097623 | 0.75 | GPR119 (0.39) | GPR119EPHX2CHRM4HRH3HRH2 | |
| SCHEMBL242303 | 0.73 | HSD11B1 (0.42) | GPR119 | |
| SCHEMBL1168816 | 0.71 | HSD11B1 (0.45) | IDH1 | |
| SCHEMBL14097603 | 0.71 | GPR119 (0.43) | GPR119HRH3HRH2HRH1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | claimed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | claimed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | claimed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | claimed |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | GPR119 162/4885ADAM17 2824/4885EPHX2 1354/4885 |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD17B1 | GPR119 182/4885ADAM17 2543/4885EPHX2 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.